Effect of 24-h continuous rotigotine treatment on stationary and non-stationary locomotion in de novo patients with Parkinson disease in an open-label uncontrolled study

Serrao, Mariano; Ranavolo, Alberto; Conte, Carmela; Davassi, Chiara; Mari, Silvia; Fasano, Alfonso; Chini, Giorgia; Draicchio, Francesco; Pierelli, Francesco

doi:10.1007/s00415-015-7883-4

Cited by 18 publications

(11 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An open-label uncontrolled study evaluated transdermal patch rotigotine as monotherapy in untreated PD patients for 6 months and found that transdermal patch rotigotine improved all aspects of gait compared to baseline, including straight walking, gait initiation and turning [100]. Studies of DA as an adjunct to levodopa also found beneficial effects on gait speed in add-on therapy of apomorphine (sublingual) and pramipexole compared to levodopa alone [101,102].…”

Section: Dopamine Agonists (Da)mentioning

confidence: 99%

Freezing of gait in Parkinson’s disease: pathophysiology, risk factors and treatments

Gao

Tan

et al. 2020

Transl Neurodegener

130

View full text Add to dashboard Cite

Background: Freezing of gait (FOG) is a common, disabling symptom of Parkinson's disease (PD), but the mechanisms and treatments of FOG remain great challenges for clinicians and researchers. The main focus of this review is to summarize the possible mechanisms underlying FOG, the risk factors for screening and predicting the onset of FOG, and the clinical trials involving various therapeutic strategies. In addition, the limitations and recommendations for future research design are also discussed. Main body: In the mechanism section, we briefly introduced the physiological process of gait control and hypotheses about the mechanism of FOG. In the risk factor section, gait disorders, PIGD phenotype, lower striatal DAT uptake were found to be independent risk factors of FOG with consistent evidence. In the treatment section, we summarized the clinical trials of pharmacological and non-pharmacological treatments. Despite the limited effectiveness of current medications for FOG, especially levodopa resistant FOG, there were some drugs that showed promise such as istradefylline and rasagiline. Non-pharmacological treatments encompass invasive brain and spinal cord stimulation, noninvasive repetitive transcranial magnetic stimulation (rTMS) or transcranial direct current stimulation (tDCS) and vagus nerve stimulation (VNS), and physiotherapeutic approaches including cues and other training strategies. Several novel therapeutic strategies seem to be effective, such as rTMS over supplementary motor area (SMA), dual-site DBS, spinal cord stimulation (SCS) and VNS. Of physiotherapy, wearable cueing devices seem to be generally effective and promising.Conclusion: FOG model hypotheses are helpful for better understanding and characterizing FOG and they provide clues for further research exploration. Several risk factors of FOG have been identified, but need combinatorial optimization for predicting FOG more precisely. Although firm conclusions cannot be drawn on therapeutic efficacy, the literature suggested that some therapeutic strategies showed promise.

show abstract

Section: Dopamine Agonists (Da)mentioning

confidence: 99%

Freezing of gait in Parkinson’s disease: pathophysiology, risk factors and treatments

Gao

Tan

et al. 2020

Transl Neurodegener

130

View full text Add to dashboard Cite

show abstract

“…Whilst the severity of freezing of gait (FOG) is thought to lessen with dopaminergic medications, it has been reported that FOG may be less prevalent in those not treated with levodopa (Garcia-Ruiz, 2011; Koehler et al, 2019;Nonnekes et al, 2020). Additionally, the use of dopamine agonists, which augment the effects of levodopa, may lead to an increased risk of falling or induce FOG (Serrao et al, 2015). Furthermore, the effects of dopaminergic medications lessen with disease progression (Jenner, 2015) and long-term use of dopaminergic therapies typically leads to involuntary movements known as dyskinesia (Iravani and Jenner, 2011).…”

Section: The Role Of Levodopa In Pd Gait Progressionmentioning

confidence: 99%

Gait Progression Over 6 Years in Parkinson’s Disease: Effects of Age, Medication, and Pathology

Wilson

Alcock

Yarnall

et al. 2020

Front. Aging Neurosci.

View full text Add to dashboard Cite

Background: Gait disturbance is an early, cardinal feature of Parkinson's disease (PD) associated with falls and reduced physical activity. Progression of gait impairment in Parkinson's disease is not well characterized and a better understanding is imperative to mitigate impairment. Subtle gait impairments progress in early disease despite optimal dopaminergic medication. Evaluating gait disturbances over longer periods, accounting for typical aging and dopaminergic medication changes, will enable a better understanding of gait changes and inform targeted therapies for early disease. This study aimed to describe gait progression over the first 6 years of PD by delineating changes associated with aging, medication, and pathology. Methods: One-hundred and nine newly diagnosed PD participants and 130 controls completed at least two gait assessments. Gait was assessed at 18-month intervals for up to 6 years using an instrumented walkway to measure sixteen spatiotemporal gait characteristics. Linear mixed-effects models assessed progression. Results: Ten gait characteristics significantly progressed in PD, with changes in four of these characteristics attributable to disease progression. Age-related changes also contributed to gait progression; changes in another two characteristics reflected both aging and disease progression. Gait impairment progressed irrespective of dopaminergic medication change for all characteristics except step width variability. Conclusions: Discrete gait impairments continue to progress in PD over 6 years, reflecting a combination of, and potential interaction between, disease-specific progression and age-related change. Gait changes were mostly unrelated to dopaminergic medication adjustments, highlighting limitations of current dopaminergic therapy and the need to improve interventions targeting gait decline.

show abstract

“…The specific effect of dopamine agonists as monotherapy has been evaluated in an open-label uncontrolled study with previously-untreated subjects with PD. In this study, six month use of the transdermal patch rotigotine improved all aspects of gait compared to baseline, including straight walking, gait initiation and turning [71]. …”

Section: Other Antiparkinsonian Drugsmentioning

confidence: 99%

Pharmacological treatment in Parkinson's disease: Effects on gait

Smulders

Dale

Carlson‐Kuhta

et al. 2016

Parkinsonism & Related Disorders

139

129

View full text Add to dashboard Cite

Gait impairments are a hallmark of Parkinson's disease (PD), both as an early symptom and an important cause of disability later in the disease course. Although levodopa has been shown to improve gait speed and step length, the effect of dopamine replacement therapy on other aspects of gait is less well understood. In fact, falls are not reduced and some aspects of postural instability during gait are unresponsive to dopaminergic treatment. Moreover, many medications, other than dopaminergic agents, can benefit or impair gait in people with PD. We review the effects of pharmacological interventions used in PD on gait, discriminating, whenever possible, among effects on four components of everyday mobility: straight walking, gait initiation, turning, gait adaptability. Additionally, we summarize the effects on freezing of gait. There is substantial evidence for improvement of spatial characteristics of simple, straight-ahead gait with levodopa and levodopa-enhancing drugs. Recent work suggests that drugs aiming to enhance the acetylcholine system might improve gait stability measures. There is a lack of well-designed studies to evaluate effects on more complex, but highly relevant walking abilities such as turning and flexible adjustments of gait. Finally, paucity in the literature exists on detrimental effects of drugs used in PD that are known to worsen gait and postural stability in the elderly population.

show abstract

Effect of 24-h continuous rotigotine treatment on stationary and non-stationary locomotion in de novo patients with Parkinson disease in an open-label uncontrolled study

Cited by 18 publications

References 30 publications

Freezing of gait in Parkinson’s disease: pathophysiology, risk factors and treatments

Freezing of gait in Parkinson’s disease: pathophysiology, risk factors and treatments

Gait Progression Over 6 Years in Parkinson’s Disease: Effects of Age, Medication, and Pathology

Pharmacological treatment in Parkinson's disease: Effects on gait

Contact Info

Product

Resources

About